Posts by Matthew R. Smith, MD, PhD
-
Triple Therapy Prolongs Survival in High-Volume and Any-Risk Metastatic Hormone-sensitive Prostate Cancer
Matthew R. Smith, MD, PhD, and colleagues found that in patients with high-volume, high-risk, or low-risk metastatic hormone-sensitive prostate cancer, treatment with darolutamide, androgen-deprivation therapy, and docetaxel increased overall survival with a similar safety profile across subgroups.
-
Darolutamide Delays Metastasis and Death in Patients with Nonmetastatic, Castration-Resistant Prostate Cancer
Matthew R. Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, and colleagues demonstrated in a worldwide phase 3 trial in patients with nonmetastatic, castration-resistant prostate cancer that darolutamide reduced the risk of metastasis or death from any cause by 59%.
Biography
Dr. Matthew R. Smith is Director of the Genitourinary Oncology Program at Mass General Cancer Center and a Professor of Medicine at Harvard Medical School. He graduated summa cum laude from Canisius College with a B.A. in biochemistry. He received his MD and PhD degrees from Duke University School of Medicine. He trained in Internal Medicine at Brigham and Women's Hospital. He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology. He is an internationally recognized expert in prostate cancer. He has published extensively on treatment and prevention of bone metastases and prostate cancer survivorship. He has authored more than 150 peer-reviewed articles including manuscripts in New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research. His research is supported by competitive grants and awards from the National Institutes of Health, Lance Armstrong Foundation Research Award, and the Prostate Cancer Foundation.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
